Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Last-Minute Pushback On Janssen’s EU Spravato Approval

Third Parties Intervene After CHMP Supports Drug’s EU-Wide Approval

Executive Summary

What is in store for esketamine after third parties submit written interventions to the European Medicines Agency?

You may also be interested in...



Janssen’s Spravato Clears Hurdles To Secure EU Approval

Spravato has been approved for treatment-resistant depression in the EU notwithstanding last-minute objections by third parties.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.

First Ebola Vaccine Among Seven Products To Get EMA Nod

Seven new products, including the world’s first ever Ebola vaccine, are on track to receive EU-wide approval. Meanwhile, two drugs have failed to make the grade.

Related Content

Topics

UsernamePublicRestriction

Register

PS141386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel